2022
MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features
Petukhova-Greenstein A, Zeevi T, Yang J, Chai N, DiDomenico P, Deng Y, Ciarleglio M, Haider SP, Onyiuke I, Malpani R, Lin M, Kucukkaya AS, Gottwald LA, Gebauer B, Revzin M, Onofrey J, Staib L, Gunabushanam G, Taddei T, Chapiro J. MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic Features. Journal Of Vascular And Interventional Radiology 2022, 33: 814-824.e3. PMID: 35460887, PMCID: PMC9335926, DOI: 10.1016/j.jvir.2022.04.006.Peer-Reviewed Original ResearchConceptsProgression-free survivalPoor progression-free survivalLiver Imaging ReportingHepatocellular carcinomaMR imaging biomarkersRadiomics signatureRadiofrequency ablationRadiomic featuresImaging biomarkersImaging ReportingFirst follow-up imagingMedian progression-free survivalRF ablationEarly-stage hepatocellular carcinomaPretreatment magnetic resonanceFirst-line treatmentMultifocal hepatocellular carcinomaSelection operator Cox regression modelTherapy-naïve patientsEarly-stage diseaseKaplan-Meier analysisCox regression modelLog-rank testFollow-up imagingPrediction of outcome
2020
Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma
Auer TA, Della Seta M, Collettini F, Chapiro J, Zschaeck S, Ghadjar P, Badakhshi H, Florange J, Hamm B, Budach V, Kaul D. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma. Acta Radiologica 2020, 62: 1200-1207. PMID: 32938221, DOI: 10.1177/0284185120953796.Peer-Reviewed Original ResearchConceptsProgression-free survivalOverall survivalTumor volumeGlioblastoma multiformeMagnetic resonance imagingMultivariable analysisCommon malignant primary brain tumorIntracranial progression-free survivalKarnofsky performance status scoreCranial magnetic resonance imagingMalignant primary brain tumorMedian overall survivalPerformance status scoreOS of patientsCox regression modelSignificant prognostic rolePrimary brain tumorsContrast-enhanced MRI sequencesQuantitative volumetric assessmentResection statusPrognostic roleMethyltransferase statusWorse prognosisEntire cohortNon-invasive methodQuantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation
Tegel BR, Huber S, Savic LJ, Lin M, Gebauer B, Pollak J, Chapiro J. Quantification of contrast-uptake as imaging biomarker for disease progression of renal cell carcinoma after tumor ablation. Acta Radiologica 2020, 61: 1708-1716. PMID: 32216452, PMCID: PMC7529766, DOI: 10.1177/0284185120909964.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Renal CellContrast MediaDisease ProgressionFemaleHumansImaging, Three-DimensionalKidney NeoplasmsMaleMiddle AgedNeoplasm StagingRadiography, InterventionalRetrospective StudiesSensitivity and SpecificityTumor BurdenUltrasonography, InterventionalConceptsProgression-free survivalTotal tumor volumeRenal cell carcinomaCell carcinomaOdds ratioTumor volumeImaging biomarkersImage-guided thermal ablationPrognosis of patientsRENAL nephrometry scoreCox regression modelLargest tumor diameterLog-rank testKaplan-Meier plotsCross-sectional imagingSensitive imaging biomarkerMetastatic diseaseSecondary outcomesPrimary outcomeDistant metastasisNephrometry scoreTumor diameterOutcome parametersLesion vascularityTNM stage